GetRelief Rx Review
Best for: buyers specifically seeking sublingual (non-injectable) compounded GLP-1 drops who understand the bioavailability trade-offs and lack of human PK data for this formulation
Get Relief RX, LLC (getreliefrx.com) is a Billings, Montana-based telehealth offering compounded SUBLINGUAL semaglutide (6mg, 9mg) and compounded SUBLINGUAL tirzepatide (7.5mg, 13mg, 16mg). NPI 1306697834. BBB accredited (A rating, March 2026). Free online assessment by licensed provider. Multi-state operations (20+ states). Sublingual drops only — no injectable or FDA-approved brand-name options.
Medium confidence · Last verified 2026-04-10 via YMYL multi-source pass · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
GetRelief Rx is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
GetRelief Rx prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| Tirzepatide 16mg kickoff (sublingual) | compounded | $179 |
| Semaglutide 9mg (sublingual) | compounded | $269 |
✓ Pros
- •Both compounded semaglutide and tirzepatide available at publicly displayed pricing — no login wall to see costs
- •BBB accredited with A rating (March 2026); NPI 1306697834 is independently verifiable
- •Free online assessment — no upfront consultation fee before prescribing decision
✗ Cons
- •SUBLINGUAL ONLY — no injectable option. Sublingual compounded semaglutide and tirzepatide have NOT been tested in human pharmacokinetic studies; mouse models suggest 5-8x higher doses needed to match subcutaneous bioavailability. Readers should understand this is NOT the same delivery method studied in STEP/SURMOUNT trials.
- •REGULATORY FLAG: GetReliefRX continues to offer compounded tirzepatide as of April 2026, after FDA ended enforcement discretion for tirzepatide compounding (March 19, 2025 for 503B, April 22, 2025 for 503A). The legal basis may be state-level exemptions, but this is not publicly disclosed on the site.
- •No LegitScript, PCAB, or NABP certifications identified — BBB accreditation is not a pharmacy-specific compliance credential
- •Prescriber credentials are described generically as 'licensed clinicians' without specifying MD/DO/NP/PA breakdown
Ready to start with GetRelief Rx?
Starting at $179/month. See current pricing and start your free consultation.
Sources & methodology
Our GetRelief Rx review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to GetRelief Rx
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with GetRelief Rx?
Starting at $179/month. See current pricing and start your free consultation.